Double attack on prostate tumors before removal
NCT ID NCT00329043
Summary
This study tested whether adding the drug sunitinib to standard hormone therapy could better shrink or control prostate tumors in men scheduled for prostate removal surgery. It involved 64 men with high-risk, localized prostate cancer. The goal was to see if this combination treatment before surgery could improve outcomes by reducing the cancer burden first.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.